The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bai, X.-F.
Right arrow Articles by Liu, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bai, X.-F.
Right arrow Articles by Liu, Y.
The Journal of Immunology, 2001, 167: 3936-3943.
Copyright © 2001 by The American Association of Immunologists

Local Costimulation Reinvigorates Tumor-Specific Cytolytic T Lymphocytes for Experimental Therapy in Mice with Large Tumor Burdens1

Xue-Feng Bai, Jonathan Bender, Jinqing Liu, Huiming Zhang, Yin Wang, Ou Li, Peishuang Du, Pan Zheng2 and Yang Liu2

Department of Pathology and Comprehensive Cancer Center, Ohio State University Medical Center, Columbus, OH 43210

Cytotoxic T cells recognize tumor Ags and destroy cancer cells in vitro. Adoptive transfer studies with transgenic T cells specific for tumor Ags have demonstrated that CTL are effective only in mice with small tumor burdens and thus appear to have limited potential in cancer immunotherapy. Here we used transgenic mice that express the TCR specific for an unmutated tumor Ag P1A and multiple lineages of P1A-expressing tumors to address this critical issue. We found that local costimulation, either by expression of B7-1 on the tumor cells or by local administration of anti-CD28 mAb 37N, reinvigorated the function of CTL specific for the tumor Ag, as it substantially increased the efficacy of CTL therapy for mice with large tumor burdens. Our study suggests that CTL-based immunotherapy can be manipulated to deal with large tumors.




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
A. Bai, E. Higham, H. N. Eisen, K. D. Wittrup, and J. Chen
From the Cover: Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice
PNAS, September 2, 2008; 105(35): 13003 - 13008.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. F. May Jr, K. Lute, E. Kocak, S. Abdessalam, L. Yin, O. Li, Z. Guan, G. Philips, P. Zheng, and Y. Liu
Immune competence of cancer-reactive T cells generated de novo in adult tumor-bearing mice
Blood, January 1, 2007; 109(1): 253 - 258.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X.-F. Bai, J.-Q. Liu, P. S. Joshi, L. Wang, L. Yin, J. Labanowska, N. Heerema, P. Zheng, and Y. Liu
Different Lineages of P1A-Expressing Cancer Cells Use Divergent Modes of Immune Evasion for T-Cell Adoptive Therapy
Cancer Res., August 15, 2006; 66(16): 8241 - 8249.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Zheng, S. Liu, P. Wang, Y. Xu, and A. Chen
Arming Tumor-Reactive T Cells with Costimulator B7-1 Enhances Therapeutic Efficacy of the T Cells.
Cancer Res., July 1, 2006; 66(13): 6793 - 6799.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
A. B. Frey and N. Monu
Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response
J. Leukoc. Biol., April 1, 2006; 79(4): 652 - 662.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. P.F. Gade, W. Hassen, E. Santos, G. Gunset, A. Saudemont, M. C. Gong, R. Brentjens, X.-S. Zhong, M. Stephan, J. Stefanski, et al.
Targeted Elimination of Prostate Cancer by Genetically Directed Human T Lymphocytes
Cancer Res., October 1, 2005; 65(19): 9080 - 9088.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
X. Zheng, J.-X. Gao, X. Chang, Y. Wang, Y. Liu, J. Wen, H. Zhang, J. Zhang, Y. Liu, and P. Zheng
B7-CD28 Interaction Promotes Proliferation and Survival but Suppresses Differentiation of CD4-CD8- T Cells in the Thymus
J. Immunol., August 15, 2004; 173(4): 2253 - 2261.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Sarma, X.-F. Bai, J.-q. Liu, K. F. May Jr., P. Zheng, and Y. Liu
On the Role of Unmutated Antigens in Tumor Rejection in Mice with Unperturbed T-cell Repertoires
Cancer Res., September 15, 2003; 63(18): 6051 - 6055.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. F. May Jr., L. Chen, P. Zheng, and Y. Liu
Anti-4-1BB Monoclonal Antibody Enhances Rejection of Large Tumor Burden by Promoting Survival but not Clonal Expansion of Tumor-specific CD8+ T Cells
Cancer Res., June 1, 2002; 62(12): 3459 - 3465.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
X.-F. Bai, J. Liu, K. F. May Jr, Y. Guo, P. Zheng, and Y. Liu
B7-CTLA4 interaction promotes cognate destruction of tumor cells by cytotoxic T lymphocytes in vivo
Blood, April 15, 2002; 99(8): 2880 - 2889.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
X. Liu, X.-F. Bai, J. Wen, J.-X. Gao, J. Liu, P. Lu, Y. Wang, P. Zheng, and Y. Liu
B7H Costimulates Clonal Expansion of, and Cognate Destruction of Tumor Cells by, CD8+ T Lymphocytes In Vivo
J. Exp. Med., November 5, 2001; 194(9): 1339 - 1348.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2001 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2001 by The American Association of Immunologists, Inc. All rights reserved.